TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cann Group ( (AU:CAN) ) has shared an announcement.
Cann Group Limited announced the successful results of its Annual General Meeting, where all resolutions were carried out through a poll. The meeting included the adoption of the remuneration report, re-election of a director, and approval of various share and option issuances. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives in the cannabis industry.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited is an Australian company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. The company operates research facilities and corporate headquarters in Melbourne and has a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group offers a range of dried flower and oil products, active pharmaceutical ingredients, and extracts to customers in Australia and globally. The company also owns Satipharm and its patent-protected capsule technology.
Average Trading Volume: 3,938,058
Technical Sentiment Signal: Sell
Current Market Cap: A$9.58M
Learn more about CAN stock on TipRanks’ Stock Analysis page.